Felzartamab

• CAT Number: I042105
• CAS Number: 2197112-39-1
• Purity: ≥95%

Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research[1][2].
The MOR202-mediated toxic effects on multiple myeloma (MM) cell lines can be enhanced by the proteasome inhibitor bortezomib (BOR) and the immunomodulator lenalidomide (LEN)[1].
MOR202 can reduce osteolysis dose-dependently by up to 55% at 12 mg/kg. Co-administration with 0.6 mg/kg BOR or 50 mg/kg LEN at a low dose of 3 mg/kg completely eliminates osteolysis in mice MM model[1].

Reference

[1]. J. Endell, et al. Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma.Meeting Abstract | 2011 ASCO Annual Meeting I

[2]. Marc S Raab, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 2020 May;7(5):e381-e394.
 [Content Brief]